CHR10 Antibody

Overview of CCR10

CCR10 (C-C chemokine receptor type 10) is a G-protein-coupled receptor that binds chemokines CCL27 (cutaneous T-cell-attracting chemokine) and CCL28 (mucosae-associated epithelial chemokine) . Key characteristics include:

CCR10 Antibody Characteristics

Antibodies targeting CCR10 are critical for studying its role in immune responses. Examples from commercial and research contexts include:

Key Antibody Clones

Technical Applications

• Flow Cytometry: Used to detect CCR10 on human peripheral blood lymphocytes and transfected cell lines .

• Immunohistochemistry: Staining reveals CCR10 expression in inflammatory lesions (e.g., muscle biopsies in murine myositis models) .

Role in Autoimmune Diseases

• Polymyositis Model: Anti-CXCL10 (a related chemokine) antibody treatment reduced muscle inflammation in mice, suggesting CCR10/CXCR3 axis involvement in T-cell-mediated pathology .

• Rheumatoid Arthritis (RA): Although not directly targeting CCR10, anti-CXCL10 monoclonal antibodies (e.g., MDX-1100) showed efficacy in RA patients, highlighting chemokine pathways as therapeutic targets .

Mechanistic Insights

• Antibody-Dependent Enhancement: In respiratory syncytial virus (RSV) infections, antibodies enhance CXCL10 production in infant immune cells, potentially exacerbating inflammation via CCR10/CXCR3 interactions .

• Ligand Binding Specificity: Antibody neutralization of CXCL10 in vivo depends on binding to both the chemokine and Fc receptors, underscoring functional complexity .

Clinical and Preclinical Implications

Limitations and Future Directions

• Target Specificity: Some anti-CCR10 antibodies exhibit cross-reactivity with non-human primates (e.g., cynomolgus, rhesus) .

• Therapeutic Potential: Bispecific antibodies (e.g., HIV-targeting 10E8.4/iMab) demonstrate engineered applications, though CCR10-focused therapies remain exploratory .